Thursday, July 19, 2012
A team of NIH
researchers has linked phosphoinositide
to neuregulin signaling and shown
that inhibiting the kinase improved behavior in rodent models of schizophrenia.1
The findings could offer a way to target the neuregulin pathway, which has been
associated with schizophrenia for more than a decade but has eluded drug
discovery efforts because of a lack of validated targets.
Fulmer, T. SciBX 5(28); doi:10.1038/scibx.2012.718 Published online July
1. Law, A.J. et al.
Proc. Natl. Acad. Sci. USA; published online June 11, 2012;
doi:10.1073/pnas.1206118109 Contact: Amanda J. Law, National
Institutes of Health, Bethesda,
Md. e-mail: firstname.lastname@example.org
2. Mei, L. & Xiong,
W.-C. Nat. Rev. Neurosci. 9, 437-452 (2008)
3. Stefansson, H. et
al. Am. J. Hum. Genet. 71, 877-892 (2002)
4. Law, A.J. et al.
Hum. Mol. Genet. 16, 129-141 (2007)
5. Allen, N.C. et al.
Nat. Genet. 40, 827-834 (2008)
6. Shi, J. et al.
Nature 460, 753-757 (2009)
7. Chen, Y.-J.J. et al.
J. Neurosci. 28, 6872-6883 (2008)
8. Chen, J. et al.
Biol. Psychiatry 59, 1180-1188 (2006)
9. Hahn, C.-G. et al.
Nat. Med. 12, 824-828 (2006)
AND INSTITUTIONS MENTIONED
Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif.
National Institute of Mental Health, Bethesda, Md.
National Institutes of Health, Bethesda, Md.
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa.